Table 1 The baseline characteristics of all included studies in the NMA for advanced EGFR-mutated NSCLC patients

EURTAC, 2012 (III, non-Asian)

86/87; 65/65

64/62

NG

NG

Erlotinib

Chemotherapy (cisplatin + docetaxel)

Progression-free survival

OPTIMAL, 2011 (III, Asian)

82/72; 57/59

59/60

63/51

19/21

Erlotinib

Chemotherapy (gemictabine + caboplatin)

Progression-free survival, over-all survival

FLAURA, 2018 (III, multiple)

279/277; 64/64

64/62

NG

NG

Osimertinib

Gefitinib/Erlotinib

Progression-free survival, over-all survival

RELAY, 2019 (III, multiple)

224/225; 65/64

63/63

102/114

122/111

Erlotinib + ramucirumab

Erlotinib

Progression-free survival

ACTIVE, 2020 (III, Asian)

157/156; 57/60

58/60.3

117/113

40/43

Gefitinib + apatini

Gefitinib

Progression-free survival

JMIT, 2016/2019 (II, Asian)

126/65; 62/62

65.1/63.1

79/43

47/22

Gefitinib + pemetrexed

Gefitinib

Progression-free survival

NEJ009, 2020 (III, Asian)

170/172; NG

67.1/62.8

NG

NG

Gefitinib + pemetrexed +  + carboplatin

Gefitinib

Progression-free survival, over-all survival

Han et al., 2017/2020 (II, Asian)

40/41; NG

62.5/56.1

27/27

13/14

Gefitinib + pemetrexed + carboplatin

Gefitinib

Progression-free survival

ARCHER1050, 2017/2018 (III, multiple)

227/225; 62/61

64.3/55.6

133/140

94/85

Dacomitinib

Gefitinib

Progression-free survival, over-all survival

LUX-LUNG 3, 2013/2015 (III, multiple)

230/115; 61.5/61

63.9/67

NG

NG

Afatinib

Chemotherapy (pemetrexed + cisplatin)

Progression-free survival, over-all survival

LUX-LUNG 6, 2014/2015 (III, Asian)

242/122; 58/58

64/68

NG

NG

Afatinib

Chemotherapy (gemcitabine + cisplatin)

Progression-free survival, over-all survival

LUX-LUNG 7, 2016/2017 (IIb, multiple)

160/159; 63/63

56.9/66.7

NG

NG

Afatinib

Gefitinib

Progression-free survival, over-all survival